Company news

Biodesix, Inc. (NASDAQ:BDSX) news

Every Biodesix, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.

View Biodesix, Inc. stock analysis →

Press releases & updates

Biodesix to Participate in Canaccord Genuity’s 46th Annual Growth Conference

August 4, 2026

Biodesix to Report Second Quarter 2026 Financial Results on August 5, 2026

July 22, 2026

Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Te...

May 11, 2026

Biodesix Announces First Quarter 2026 Results and Highlights

May 4, 2026

Biodesix Recognized as a Top Workplace for Third Consecutive Year

April 9, 2026

Biodesix Announces AACR 2026 Posters and Presentations, Highlighting Novel Diagnostic Test Discovery & Pipeline Development

April 6, 2026

Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validation Study Ever Published Supporting Earlier Lung Cancer Diagnosis

March 20, 2026

Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights

February 26, 2026

Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

February 12, 2026

Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited)

January 12, 2026

Biodesix to Present New Data at Two Major Upcoming Scientific Meetings

December 3, 2025

Biodesix Announces Third Quarter 2025 Results and Highlights

November 3, 2025

Biodesix to Share its R&D Roadmap during its Corporate Day Presentation at AMP Annual Meeting

October 30, 2025

Biodesix Announces Expanded Bio-Rad Laboratories Partnership Agreement to Develop Droplet Digital™ PCR High Complexity Assays

October 22, 2025

Biodesix Announces Presentations and Events at the CHEST 2025 Annual Meeting

October 15, 2025

Biodesix Unveils October Lung Health Events in Colorado with the Association of Pulmonary Advanced Practice Providers (APAPP), American L...

October 6, 2025

Biodesix Announces One-for-Twenty Reverse Stock Split

September 11, 2025

Biodesix to Participate in Lake Street Capital Markets’ 9th Annual Best Ideas Growth (BIG9) Conference

September 5, 2025

Biodesix Recognized as a Thermo Fisher Scientific Center of Excellence (COE) for NGS Diagnostics

August 19, 2025

Biodesix Announces Second Quarter 2025 Results and Highlights

August 7, 2025

Biodesix to Present at the Canaccord Genuity 45th Annual Growth Conference

August 5, 2025

Biodesix to Report Second Quarter 2025 Financial Results on August 7, 2025

July 24, 2025

Biodesix Partners with Association of Pulmonary Advanced Practice Providers (APAPP) to Deliver Nation’s First Medical Education for APPs ...

June 10, 2025

Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting

May 22, 2025

Biodesix to Participate in Upcoming Investor Conferences

May 21, 2025

Biodesix Announces New Clinical and Economic Data for its Nodify Lung® Tests at ISPOR and ATS

May 15, 2025

Denver Post Names Biodesix a Winner of Top Workplaces 2025 Award

May 14, 2025

Biodesix Announces First Quarter 2025 Results and Highlights

May 13, 2025

Biodesix to Report First Quarter 2025 Financial Results on May 13, 2025

April 29, 2025

Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA ...

April 23, 2025

Biodesix Announces Fourth Quarter and Fiscal Year 2024 Results

March 3, 2025

Biodesix to Present at TD Cowen 45th Annual Health Care Conference

February 26, 2025

Biodesix to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

February 18, 2025

Biodesix Announces Preliminary Fourth Quarter and Full-Year 2024 Results (Unaudited)

January 10, 2025

Biodesix Announces Publication of a New Nodify CDT® Clinical Validation Study

January 7, 2025

Biodesix Announces Third Quarter 2024 Results and Highlights

November 1, 2024

Biodesix Announces New Data Presentation at CHEST 2024 Annual Meeting and the Launch of a Complementary Clinical Study

October 7, 2024

Biodesix Announces Second Quarter 2024 Results and Highlights

August 7, 2024

Biodesix Announces First Quarter 2024 Results Driven by Growth in Lung Diagnostic Testing for Lung Nodule Management

May 8, 2024

Biodesix to Report First Quarter 2024 Financial Results on May 8, 2024

April 24, 2024

Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private Placement

April 5, 2024

Biodesix Announces New Master Collaborative Research Agreement with Leading US Cancer Center

March 25, 2024

Biodesix Announces Fourth Quarter and Fiscal Year 2023 Results and Business Highlights

March 1, 2024

Biodesix to Report Fourth Quarter and Full Year 2023 Financial Results on March 1, 2024

February 16, 2024

Biodesix Enhances Access to Nodify Lung® Testing with Launch of New Blood Draw Method

November 14, 2023

Biodesix Announces Third Quarter 2023 Results and Highlights

November 7, 2023

Biodesix to Report Third Quarter 2023 Financial Results on November 7, 2023

October 24, 2023

Biodesix Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer

September 7, 2023

Biodesix Announces Presentation of New Nodify XL2® Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing Cancer

August 22, 2023

Biodesix Announces Second Quarter 2023 Results and Highlights

August 7, 2023

Older →